These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 9829028)

  • 1. Pharmacotherapy for obsessive-compulsive disorder.
    Greist JH; Jefferson JW
    Br J Psychiatry Suppl; 1998; (35):64-70. PubMed ID: 9829028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurobiology and clinical pharmacology of obsessive-compulsive disorder.
    Micallef J; Blin O
    Clin Neuropharmacol; 2001; 24(4):191-207. PubMed ID: 11479390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
    Todorov C; Freeston MH; Borgeat F
    Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
    Vythilingum B; Cartwright C; Hollander E
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
    de Oliveira MVS; de Barros PMF; de Mathis MA; Boavista R; Chacon P; Echevarria MAN; Ferrão YA; Vattimo EFQ; Lopes AC; Torres AR; Diniz JB; Fontenelle LF; Rosário MCD; Shavitt RG; Miguel EC; da Silva RMF; Costa DLDC
    Braz J Psychiatry; 2023 May; 45(2):146-161. PubMed ID: 36749887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The medical treatment of obsessive-compulsive disorder and anxiety.
    Bandelow B
    CNS Spectr; 2008 Sep; 13(9 Suppl 14):37-46. PubMed ID: 18849910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for obsessive-compulsive disorder.
    Hollander E; Kaplan A; Allen A; Cartwright C
    Psychiatr Clin North Am; 2000 Sep; 23(3):643-56. PubMed ID: 10986733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.
    Fineberg NA; Reghunandanan S; Brown A; Pampaloni I
    Aust N Z J Psychiatry; 2013 Feb; 47(2):121-41. PubMed ID: 23125399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
    Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
    BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of obsessive-compulsive disorder.
    Ko SM
    Br J Clin Pract; 1995; 49(1):36-9. PubMed ID: 7742183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
    Figgitt DP; McClellan KJ
    Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.